Results 21 to 30 of about 11,886 (196)

Placental disposition of eculizumab, C5 and C5‐eculizumab in two pregnancies of a woman with paroxysmal nocturnal haemoglobinuria [PDF]

, 2021
Contains fulltext : 232079.pdf (Publisher’s version ) (Open Access)Eculizumab is known to cross the placenta to a limited degree, but recently therapeutic drug levels in cord blood were found in a single case.
Petra H.H. van den Broek, Joris van Drongelen, Olivier W.H. van der Heijden, Broek, P.H.H. van den, Russel, F.G.M., Rick Greupink, Sarlea, A., Heijden, O.W.H. van der, Eliesen, G.A.M., Drongelen, J. van, Volokhina, E.B., Andrei Sarlea, Elena B. Volokhina, Frans G.M. Russel, Gaby A.M. Eliesen, Langemeijer, S.M., Saskia Langemeijer, Greupink, R.   +17 more
core   +1 more source

Long-Term Safety and Efficacy of Eculizumab in Aquaporin-4 IgG-Positive NMOSD [PDF]

, 2021
Objective: During PREVENT (NCT01892345), eculizumab significantly reduced relapse risk versus placebo in patients with aquaporin-4 immunoglobulin G-positive neuromyelitis optica spectrum disorder (AQP4-IgG+ NMOSD).
Berthele, A, Oreja-Guevara, C, Sabatella, G, Nakashima, I, Fujihara, K, Miller, L, Kim, HJ, Yountz, M, Winkel, Antony, Palace, J, Wingerchuk, DM, Levy, M, Pittock, SJ, Shang, S, Wang, KC, et al.   +15 more
core   +1 more source

Eculizumab Pharmacokinetics and Pharmacodynamics in Patients With Neuromyelitis Optica Spectrum Disorder

Frontiers in Neurology, 2021
Objective: To investigate the pharmacokinetics and pharmacodynamics of the approved 900/1,200 mg dosing regimen for the terminal complement component 5 (C5) inhibitor eculizumab in patients with neuromyelitis optica spectrum disorder (NMOSD).Methods ...
Pratap Singh, Xiang Gao, Huub Jan Kleijn, Francesco Bellanti, Ryan Pelto   +4 more
doaj   +1 more source

Case Report: Variable Pharmacokinetic Profile of Eculizumab in an aHUS Patient

Frontiers in Immunology, 2021
BackgroundWith the introduction of eculizumab, a C5-inhibitor, morbidity and mortality improved significantly for patients with atypical hemolytic uremic syndrome (aHUS).
Romy N. Bouwmeester, Mendy Ter Avest, Kioa L. Wijnsma, Caroline Duineveld, Rob ter Heine, Elena B. Volokhina, Lambertus P. W. J. Van Den Heuvel, Jack F. M. Wetzels, Nicole C. A. J. van de Kar   +8 more
doaj   +1 more source

Data_Sheet_2_Utilization Pattern for Eculizumab Among Children With Hemolytic Uremic Syndrome.PDF [PDF]

, 2021
Background: Hemolytic uremic syndrome (HUS) is a complex disease with multi-organ involvement. Eculizumab therapy is recommended for treatment of complement mediated hemolytic uremic syndrome (cHUS).
Rachel Millner (11522578), Parthak Prodhan (11522584), Richard Blaszak (11522575), Saritha Ranabothu (11522572), Clare C. Brown (9509210), Kristen Rice Moore (11522581)   +5 more
core   +1 more source

Eculizumab in gemcitabine-induced thrombotic microangiopathy: experience of the French thrombotic microangiopathies reference centre

BMC Nephrology, 2021
Background Gemcitabine is a broadly prescribed chemotherapy, the use of which can be limited by renal adverse events, including thrombotic microangiopathy (TMA). Methods This study evaluated the efficacy of eculizumab, a monoclonal antibody targeting the
Maximilien Grall, Florence Daviet, Noémie Jourde Chiche, François Provot, Claire Presne, Jean-Philippe Coindre, Claire Pouteil-Noble, Alexandre Karras, Dominique Guerrot, Arnaud François, Ygal Benhamou, Agnès Veyradier, Véronique Frémeaux-Bacchi, Paul Coppo, Steven Grangé   +14 more
doaj   +1 more source

Eculizumab hepatotoxicity in pediatric aHUS. [PDF]

, 2015
BACKGROUND Eculizumab is a humanized anti-C5 antibody approved for the treatment of atypical hemolytic uremic syndrome (aHUS). Its use is increasing in children following reports of its safety and efficacy.
Hayes, Wesley, Tschumi, Sibylle, Feber, Janusz, Ling, Simon C, Licht, Christoph, Kirschfink, Michael   +5 more
core   +1 more source

Meningococcemia in a vaccinated child receiving eculizumab and review of the literature

The Turkish Journal of Pediatrics, 2023
Background. Atypical hemolytic uremic syndrome (aHUS) is a rare and severe disease characterized by uncontrolled activation and dysregulation of the alternative complement pathway and development of thrombotic microangiopathy. Eculizumab, which is
Diana Üçkardeş, Nilüfer Göknar, Nurhan Kasap, Emre Keleşoğlu, Mustafa Arga, Cengiz Candan   +5 more
doaj   +1 more source

Outcomes in patients with atypical hemolytic uremic syndrome treated with eculizumab in a long-term observational study

BMC Nephrology, 2019
Background There are limited long-term outcome data in eculizumab-treated patients with atypical hemolytic uremic syndrome (aHUS). We report final results from the largest prospective, observational, multicenter study of patients with aHUS treated with ...
Jan Menne, Yahsou Delmas, Fadi Fakhouri, Christoph Licht, Åsa Lommelé, Enrico E. Minetti, François Provôt, Eric Rondeau, Neil S. Sheerin, Jimmy Wang, Laurent E. Weekers, Larry A. Greenbaum   +11 more
doaj   +1 more source

Eculizumab dosing in infants

Indian Journal of Nephrology, 2018
Eculizumab is the therapy of choice for patients with atypical hemolytic uremic syndrome (aHUS). Dosing recommendations stem from two trials: one retrospective trial (19 children and 5 infants) and one prospective trial (22 patients and 5 infants). This case report highlights the need for more precise dosing recommendations in children, particularly in
Kobrzynski, M, Wile, B, Huang, S S, Filler, G   +3 more
openaire   +4 more sources